Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 83
  • Home
  • Print this page
  • Email this page

    Article Cited by others


Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents

Wilkes Gail M

Year : 2018| Volume: 5| Issue : 2 | Page no: 137-155

   This article has been cited by
1 Ocular and orbital side effects of ALK inhibitors: a review article
Elias Chelala,Sandra Hoyek,Nicolas Arej,Joseph Kattan,Hampig Raphael Kourie,Josette Baakliny,Joelle Antoun
Future Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature
Hira Shaikh,Ahmed Khattab,Muhammad S Faisal,Abhishek Chilkulwar,Mary Albrethsen,Santhosh Sadashiv,Salman Fazal
Journal of Oncology Pharmacy Practice. 2019; 25(5): 1265
[Pubmed]  [Google Scholar] [DOI]
3 DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer
Zhongling Zhu,Peng Chen,Zhao Yan
Thoracic Cancer. 2018; 9(8): 901
[Pubmed]  [Google Scholar] [DOI]


Read this article